WO2013059060A1 - 2-methylene-vitamin d analogs and their uses - Google Patents

2-methylene-vitamin d analogs and their uses Download PDF

Info

Publication number
WO2013059060A1
WO2013059060A1 PCT/US2012/059667 US2012059667W WO2013059060A1 WO 2013059060 A1 WO2013059060 A1 WO 2013059060A1 US 2012059667 W US2012059667 W US 2012059667W WO 2013059060 A1 WO2013059060 A1 WO 2013059060A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
group
vitamin
methylene
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/059667
Other languages
English (en)
French (fr)
Inventor
Hector F. Deluca
Lori A. Plum
Rafal R. Sicinski
Izabela Sibilska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Priority to EP12781531.4A priority Critical patent/EP2768804B1/en
Priority to CA2851283A priority patent/CA2851283C/en
Priority to JP2014537120A priority patent/JP6114292B2/ja
Priority to AU2012326485A priority patent/AU2012326485B2/en
Publication of WO2013059060A1 publication Critical patent/WO2013059060A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Definitions

  • Figures 1-5 illustrate various biological activities of (20S)-la,25-dihydroxy-2- methylene-vitamin D 3 , hereinafter referred to as "2EG-S,” as compared to the native hormone lcc,25-dihydroxy vitamin D 3 , hereinafter " l ,25(OH)2D 3 .”
  • Figure 5 shows that 2EG-S has relatively high activity as compared to that of
  • Figure 2 illustrates that 2EG-S is more potent than 1 ,25(OH) 2 D 3 on HL-60 cell differentiation, making it an excellent candidate for the treatment of a cancer, especially for the prevention or treatment of osteosarcoma, leukemia, colon cancer, breast cancer, skin cancer and prostate cancer.
  • the compounds of formula I and particularly 2EG-S of formula la, and T-2EG-S of formula lb, and 2EG-R of formula Ic may be administered orally, topically, parenterally, rectally, nasally, sublingually, or transdermally.
  • the compound is advantageously administered by injection or by intravenous infusion or suitable sterile solutions, or in the form of liquid or solid doses via the alimentary canal, or in the form of creams, ointments, patches, or similar vehicles suitable for transdermal applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/US2012/059667 2011-10-21 2012-10-11 2-methylene-vitamin d analogs and their uses Ceased WO2013059060A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP12781531.4A EP2768804B1 (en) 2011-10-21 2012-10-11 2-methylene-vitamin d analogs and their uses
CA2851283A CA2851283C (en) 2011-10-21 2012-10-11 2-methylene-vitamin d analogs and their uses
JP2014537120A JP6114292B2 (ja) 2011-10-21 2012-10-11 ２−メチレン−ビタミンｄ類似体およびそれらの使用
AU2012326485A AU2012326485B2 (en) 2011-10-21 2012-10-11 2-methylene-vitamin D analogs and their uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550172P 2011-10-21 2011-10-21
US61/550,172 2011-10-21

Publications (1)

Publication Number Publication Date
WO2013059060A1 true WO2013059060A1 (en) 2013-04-25

Family

ID=47143292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/059667 Ceased WO2013059060A1 (en) 2011-10-21 2012-10-11 2-methylene-vitamin d analogs and their uses

Country Status (6)

Country Link
US (1) US8410080B1 (https=)
EP (1) EP2768804B1 (https=)
JP (1) JP6114292B2 (https=)
AU (1) AU2012326485B2 (https=)
CA (1) CA2851283C (https=)
WO (1) WO2013059060A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6971966B2 (ja) * 2015-08-05 2021-11-24 ウイスコンシン アラムニ リサーチ ファンデーション カルシトリオールの２−メチレン類似体および関連化合物の合成および生物活性

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
US5536713A (en) 1993-04-05 1996-07-16 Wisconsin Alumni Research Foundation 19-Nor-vitamin D3 compounds with substitutent at 2-position
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6382071B1 (en) 2000-08-07 2002-05-07 Gilbert A. Bertani Bola capturing apparatus
US6566352B1 (en) 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US6579861B2 (en) 2000-09-08 2003-06-17 Wisconsin Alumni Research Foundation 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392071B1 (en) 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
JPH11171859A (ja) * 1997-09-19 1999-06-29 Chugai Pharmaceut Co Ltd ビタミンｄ誘導体およびその製造方法
US6080879A (en) * 1998-05-19 2000-06-27 Tetrionics, Inc. Hexafluoro-vitamin synthesis and crystallization method, solvent and product
US6114317A (en) * 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
EP1233942A2 (en) * 1999-12-02 2002-08-28 The Penn State Research Foundation Treatment of inflammatory bowel disease with vitamin d compounds
NZ533424A (en) * 2001-12-13 2006-08-31 Wisconsin Alumni Res Found Vitamin D derivative, methods of purifying and uses in treating psoriasis, cancer, autoimmune diseases, inflammatory diseases, skin conidtions and renal ostepdystrophy
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US7259143B2 (en) * 2002-09-05 2007-08-21 Wisconsin Alumni Research Foundation Method of extending the dose range of vitamin D compounds
JP5161582B2 (ja) * 2004-11-22 2013-03-13 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １７，２０（ｚ）−デヒドロビタミンｄ類似体およびそれらの使用
EP2025667B1 (en) * 2006-06-02 2016-08-10 Nippon Shinyaku Co., Ltd. 9,10-secopregnane derivative and pharmaceutical
MX2009003241A (es) * 2006-09-28 2009-05-05 Wisconsin Alumni Res Found Analogos de 2-metilen-(20r,25s)-19,27-dinor-(22e)-vitamina d.
US8377913B2 (en) * 2007-11-20 2013-02-19 Abbvie Inc. Vitamin D receptor activators and methods of making

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
US5536713A (en) 1993-04-05 1996-07-16 Wisconsin Alumni Research Foundation 19-Nor-vitamin D3 compounds with substitutent at 2-position
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5936133A (en) 1997-03-17 1999-08-10 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6382071B1 (en) 2000-08-07 2002-05-07 Gilbert A. Bertani Bola capturing apparatus
US6579861B2 (en) 2000-09-08 2003-06-17 Wisconsin Alumni Research Foundation 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
US6566352B1 (en) 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
BAGGIOLINI ET AL., J. ORG. CHEM., vol. 51, 1986, pages 3098
BARRACK ET AL., J. ORG. CHEM., vol. 53, 1988, pages 1790
COLLINS ET AL., J. EXP. MED., vol. 149, 1979, pages 969 - 974
DATABASE PubChem Substance [Online] 19 August 2011 (2011-08-19), "CHEMBL1630752 - Substance Summary", XP002690286, retrieved from NCBI Database accession no. 124974195 (SID) *
DATABASE PubChem Substance [Online] 19 August 2011 (2011-08-19), "CHEMBL1630753 - Substance Summary", XP002690287, retrieved from NCBI Database accession no. 124961039 (SID) *
GLEBOCKA ET AL., J. MED. CHEM., vol. 49, 2006, pages 2909
GRZYWACZ ET AL., J. STEROID BIOCHEM. MOL. BIOL., vol. 89-90, 2004, pages 13
INHOFFEN ET AL., CHEM. BER., vol. 90, 1957, pages 664
J. ORG. CHEM., vol. 60, 1995, pages 4617
MASCARENAS ET AL., TETRAHEDRON, vol. 47, 1991, pages 3485
MIYAMOTO ET AL., CHEM. PHARM. BULL., vol. 41, 1993, pages 1111
NISHII ET AL., OSTEOPOROSIS INT., no. 1, 1993, pages 190
OKANO ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 163, 1989, pages 1444
OSTREM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 2610
PERLMAN ET AL., TETRAHEDRON LETT., vol. 31, 1990, pages 1823
PERLMAN, TETRAHEDRON LCTT., vol. 32, 1991, pages 7663
POSNER ET AL., J. ORG. CHEM., vol. 59, 1994, pages 7855
SANCHEZ-ABELLA ET AL., BIOORG. MED. CHEM., vol. 16, 2008, pages 10244
SICINSKI ET AL., J. MED. CHEM., vol. 41, 1998, pages 4662
SICINSKI ET AL., STEROIDS, vol. 67, no. 247, 2002
SUDA ET AL., J. NUTR., vol. 100, 1970, pages 1049
WINDAUS ET AL., ANN., vol. 524, 1936, pages 297

Also Published As

Publication number Publication date
CA2851283A1 (en) 2013-04-25
JP2014532622A (ja) 2014-12-08
CA2851283C (en) 2020-07-14
JP6114292B2 (ja) 2017-04-12
EP2768804A1 (en) 2014-08-27
EP2768804B1 (en) 2018-02-28
AU2012326485A1 (en) 2014-04-24
AU2012326485B2 (en) 2016-12-08
US20130102574A1 (en) 2013-04-25
US8410080B1 (en) 2013-04-02

Similar Documents

Publication Publication Date Title
EP2240438B1 (en) 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin d analogs
US8445468B2 (en) (20S,22E)-2-methylene-19-nor-22-ene-1α,25-dihydroxyvitamin D3
US8455467B2 (en) 2-methylene-vitamin D analogs and their uses
EP2721004B1 (en) 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
EP2483240B1 (en) 1-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
EP2768804B1 (en) 2-methylene-vitamin d analogs and their uses
US8729054B2 (en) 3-desoxy-2-methylene-vitamin D analogs and their uses
US20130178449A1 (en) 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs
US8518917B2 (en) 2-methylene-19-nor-vitamin D analogs and their uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12781531

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2851283

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014537120

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012326485

Country of ref document: AU

Date of ref document: 20121011

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012781531

Country of ref document: EP